Published November 9, 2026 · Research context, not a new FDA warning
Why the publication date matters
The Injury journal listing dates this paper online October 8, 2026. We are explaining earlier research, not announcing a new November safety finding.
What was studied
The original observational study by Mahatme and colleagues compared adults prescribed gabapentin or pregabalin together with opioids shortly after surgery for certain closed long-bone fractures against adults receiving opioids alone. Gabapentin (Neurontin) and pregabalin (Lyrica) are separate medicines; these combined results are not a gabapentin-only estimate.
In matched groups, nonunion at one year was recorded in 4.3% with combined treatment versus 1.9% with opioids alone. Nonunion means a fracture has not healed. The combined group had fewer early emergency-department visits. An alternative analysis still found a nonunion association, but associations with prolonged opioid use and reoperation were no longer statistically significant.
What this cannot establish
These were treatment records, not a randomized trial. Patient differences and prescribing decisions can influence outcomes. The study does not prove that either medicine caused failed healing, and it does not answer the separate question of dementia risk.
Make a useful record
If you have concerns after surgery, ask your treating clinician about your healing and medicines. For a legal consultation, preserve the operative report, follow-up imaging, diagnosis dates and pharmacy history. Our medication-identification guide explains why the exact drug and manufacturer matter. Review the FDA breathing-risk information for a different safety issue involving sedating medicines. Do not change treatment without your prescriber. Research alone does not establish a legal claim.
